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A B S T R A C T
A functional catechol-o-methyltransferase (COMT Val158/108Met) polymorphism, a valine (Val) to methionine (Met)
substitution, has been associated with cognitive processing in the normal brain, older age, mild cognitive impairment
and in various dementias. COMT is involved in the breakdown of dopamine and other catecholamines, especially in the
frontal cortex; hence the carriers of Met allele, with the lower enzymatic activity, are expected to perform better on particu-
lar neuro-cognitive tests. The study included 46 patients with dementia and 65 healthy older subjects. The neurological
status was assessed, using the Mini Mental Status Examination (MMSE), and the batery of different neurological tests.
In DNA samples COMT polymorphism was genotyped. Patients with dementia exhibited significant genotype-induced
differences in scores for MMSE, Visual Association Test (VAT) duration of numbers test, VAT time of response to num-
bers test, VAT average response to numbers test and WPLCR/PPLR unanswered. Carriers of Met/Met genotype had sig-
nificantly lower scores of MMSE, significantly longer time to respond to VAT duration of numbers test, VAT time of re-
sponse to numbers test and VAT average response to numbers test, and significantly greater number of unanswered
questions to WPLCR/PPLR when compared to Met/Val or Val/Val genotypes. Our preliminary data showed significantly
impaired performance in several neuro-cognitive tests in carriers of Met/Met genotype in patients with dementia com-
pared to either Met/Val or Val/Val genotype carriers. Although Met/Met genotype with more dopamine available in the
frontal cortex should be associated with better neuro-cognitive test results than Met/Val or Val/Val genotype, our data on
patients with dementia did not confirm this hypothesis. Further study on larger sample of patients is needed to clarify
the role of COMT polymorphism in cognitive functions.
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Introduction
Catechol-o-methyl-transferase (COMT) is an enzyme
that degrades catecholamines dopamine, noradrenaline
and adrenaline. Besides catecholamines, COMT inacti-
vates catecholestrogens1. COMT is widely distributed in
the human brain2, but its neurobiological effects are es-
pecially important in the prefrontal cortex where COMT
degrades dopamine, and thus regulates dopamine avail-
ability since dopamine transporters are expressed in low
abundance in the frontal cortex3,4. Prefrontal cortex has
a major role in various aspects of higher-order informa-
tion processing, and dopamine signaling is implicated in
cognitive functioning and in fine tuning of these neu-
ronal and circuit responses during executive processes5.
COMT has been proposed to represent a risk factor for
various psychiatric disorders6,7, such as attention deficit
hyperactivity disorder (ADHD), schizophrenia, substan-
ce use disorders, bipolar disorder and neurodegenerative
disorders such as Alzheimer’s disease8 and other de-
mentias, and for a possible susceptibility to psychosis in
Alzheimer’s disease9.
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COMT gene is located on chromosome 22q11. Activity
of COMT is modulated by a common functional SNP in
exon 4: Val(158/108)Met, with G to A transition at codon
158, that results in an amino-acid substitution of valine
(Val) with methionine (Met). Homozygosity for Val allele
results in a 3 to 4 fold higher COMT activity compared to
Met homozygotes, while heterozygotes have intermedi-
ate COMT activity10. The Met allele is referred as the
low-activity (L allele), whereas Val allele is more stable,
referred as a high-activity variant (H allele), associated
with greater enzymatic activity and hence greater dopa-
mine degradation than the Met allele. The functional
Val(158/108)Met polymorphism has been studied in rela-
tion to cognitive disorders in healthy subjects11–15, differ-
ent psychiatric diseases6,7, and in AD8,16, with both posi-
tive and negative results5,17. The COMT variants have
been proposed to be related to cognitive functions such as
executive functioning, working memory, attentional con-
trol, and episodic memory, cognitive and emotional infor-
mation5, and carriers of Met allele, with the lower enzy-
matic activity, are expected to perform better on particu-
lar neurocognitive tests5.
The goal of this study was to examine the association
of cognitive processes and their deficits (working mem-
ory, executive function, memory or basic attentional pro-
cesses), with COMT genetic variants.
Methods
Patients
The study included 22 male and 24 female patients
with dementia, as well as 34 male and 31 female healthy
older subjects. The participants were unrelated, medica-
tion-free Caucasian subjects of Croatian origin, who were
recruited from 2007 to 2009 at Department for Cognitive
Neurology, Zagreb University Hospital Centre, Zagreb,
Croatia. Male and female healthy subjects were 60.03±2.10
and 51.81±6.03 while male and female patients with de-
mentia were 66.67±8.24 and 72.21±7.64 years old, re-
spectively. Dementia patients comprised of patients with
Alzheimer’s disease (N=31), Fronto-temporal dementia
(N=12), Lewy Body Dementia (N=2) and Vascular de-
mentia (N=1). Diagnosis of dementia was assigned accor-
ding to results of cognitive testing, analysis of cerebro-
spinal fluid, as well as imaging using magnetic resonance
and single photon emission computed tomography.
All individuals gave their detailed medical history,
and underwent complete physical, neurological and psy-
chological examinations. Written informed consent was
obtained from all participants, after explaining the aims
and procedures of the study, under guidelines approved
by the Ethics committee of the Zagreb University Hospi-
tal Center, Zagreb, Croatia. All human studies have been
carried out with the full cooperation of participants, ade-
quate understanding, and have therefore been perfor-
med in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki.
Cognitive testing
The determination of the neurological status of these
patients utilized the Mini Mental Status Examination
(MMSE), Neuro-Psychiatric Inventory (NPI), Alzheimer’s
Disease Assessment Scale-Cognition (ADAS-COG), Clock
Drawing Test (CDT), Word pairs learning and recall/ Pic-
ture pairs learning (WPLCR/PPLR) and recall test and
Visual association test (VAT), performed by experienced
neurologists.
Mini mental state examination (MMSE)
Brief measure of cognitive status commonly used in
dementia centers. It consists of different questions that
are rated with 0 or 1 point. Scores ranges frommaximum
of 30=no impairment to 0=most severe impairment.
Neuropsychiatric inventory (NPI)
Questionnaire constructed to assess behavioral dis-
turbances occurring in dementia patients. It consists of
several different parts that are focused on delusions, hal-
lucinations, dysphoria, anxiety, agitation/aggression, eu-
phoria, disinhibiton, irritability, apathy and aberrant
motor activity. Both the frequency and the severity of
each behavior are determined. Information for the NPI is
obtained from a caregiver familiar with the patient be-
havior.
Alzheimer’s disease assessment scale-Cog
(ADAS-Cog)
Widely used and well-known scale constructed to as-
sess the level of cognitive impairment in Alzheimer’s dis-
ease. It consists of 11 different items. The rating scale of
0–5 reflects the degree of severity of dysfunction. A rat-
ing of 0 signifies no impairment on a task while a rating
of 5 is reserved for the most severe degree of impairment.
Scores ranges from 0 to 70, with 0=no impairment and
70=most severe impairment.
Visual association test (VAT)
VAT is computerized test of sustained visual attention
conceputally similar to the Conrinuous Performance Test
in that it requires participants to continously search a vi-
sual array for a target. On each trial, participants were
shown an array of 20 identical letters presented pseudo-
randomly on the screen and were instructed to conti-
nously scan the array until one of the letters changed.
Participants were instructed to respond to the change by
pressing the space bar as quickly as possible. If a trans-
formation occured and the participant did not respond
within 60 sec, that trial was considered »timed out« and
was added to the end of the session. A total of 24 trials
equally distributed over the eight delay intervals (start-
ing at 5 sec and then occuring every 15 sec) were run for
each subject. Participant’s reaction time between the ac-
tual transformation and the participant’s response was
collected.
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Word pairs learning and recall/Picture pairs
learning and recall
Test measures verbal and visual memory. The test
consists of 10 pairs of words, with 5 pairs connected by
logical association and 5 pairs of randomly connected
words. Patient is asked to memorize words and after it to
speak out the word that is missing in the pair. The pro-
cess is repeated 3 times. The number of corrected, uncor-
rected and unanswered words is measured as well as the
time requested for the answers. In the Picture pairs
learning instead of the words pictures are presented for
the patients.
COMT polymorphism analysis
DNA was extracted from blood using the DNeasy
Blood and Tissue Kit (Qiagen) according to manufac-
turer’s instructions. In DNA samples COMT Val158/
108Met polymorphism was genotyped in ABI Prism 7000
Sequencing Detection System apparatus using Taqman-
-based allele-specific polymerase chain reaction assay, ac-
cording to the procedure described by the Applied Biosys-
tems (Applied Biosystems, Foster City, CA, USA). The
primers and probes were purchased from Applied Biosys-
tems.
Statistical analysis
The results, expressed as means (X) ± standard devia-
tions (SD), were evaluated with Sigma Stat 3.5 (Jandell
Scientific Corp. San Raphael, California, USA) using
one-way analysis of variance (ANOVA), followed by the
Tukey’s test. The Hardy-Weinberg analysis was used to
test the equilibrium of the population. The differences in
the genotype frequencies were evaluated using a c2-test.
The level of significance was set to a=0.05.
Results
There were no significant differences in the genotype
(c2=3.923; d.f.=6; p=0.687) frequency between male and
female healthy subjects and patients with dementia. Sin-
ce no significant gender related differences were found,
the data for male and female subjects in the further anal-
yses were collapsed. The observed genotype distribution
in healthy control subjects (c2=0.825; p>0.05), or in pa-
tients with dementia (c2=0.999; p>0.05) did not differ
significantly from the expected Hardy–Weinberg equilib-
rium.
No significant differences in the genotype (c2=0.185;
d.f.=2; p=0.912) frequency between healthy subjects and
patients with dementia were detected. In subsequent
analyses we evaluated genotype-induced differences in
demographic and neurocognitive data in patients with
dementia. One-way ANOVA revealed significant (p=
0.026–0.043) genotype-induced differences in the MMSE
scores (Table 2), and in VAT duration of numbers test,
VAT time of response to numbers test, VAT average re-
sponse to numbers test and WPLCR/PPLR unanswered
(Table 3). Namely, carriers of Met/Val (p=0.031) or Val/
Val (p=0.015) genotype had significantly (Tukey’s test)
higher MMSE scores than Met/Met carriers (Table 3).
The post-hoc analysis (Tukey’s test) of the results ob-
tained through neurocognitive testing showed that carri-
ers of Met/Met genotype had significantly longer VAT du-
ration of numbers test (p=0.024), VAT time of response
to numbers test (p=0.024), and VAT average response to
numbers test (p=0.024), and significantly greater num-
ber of unanswered questions to WPLCR/PPLR (p=0.022)
when compared to carriers of Met/Val genotypes (Table
3). Age of the groups differed significantly (F=57.378;
df=3,107; p<0.001), since healthy subject were signifi-
cantly younger than patients with dementia.
Discussion
Our preliminary results showed similar frequency of
COMT genotypes between male and female healthy sub-
jects and male and female patients with dementia. This
finding concurs with previous studies showing similar
genotype distributions of COMT polymorphism in pa-
tients with Alzheimer’s disease and control subjects8,18.
Additionally, in line with previous report19, there were no
significant differences in COMT genotype distribution in
relation to gender. Patients with dementia differed sig-
nificantly when subdivided into Met/Met, Met/Val or
Val/Val genotypes with respect to MMSE scores, VAT du-
ration of numbers test, VAT time of response to numbers
test, VAT average response to numbers test and WPLCR/
PPLR unanswered. Namely, carriers of Met/Met geno-
type had significantly lower scores of MMSE than carri-
ers of Met/Val or Val/Val genotypes, indicating more se-
vere symptoms of dementia. In addition, carriers of Met/
Met genotype needed significantly longer time to re-
spond to VAT duration of numbers test, VAT time of re-
sponse to numbers test and VAT average response to
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TABLE 1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
OF SUBJECTS WITH DEMENTIA
Dementia; N=46
Sex female/male 24/22
Age 69.7±8.2
Duration of disease 2.5±1.8
Age at onset 67.2±8.3
Education 10. 2±4.4
MMSE 16.5±6.5
MMSE modified 54.5±22.0
CDT 5.0±2.4
ADAS 45.2±14.7
NPI 11.7±11.8
VAT 2835±4244
numbers test, and they showed significantly greater num-
ber of unanswered questions to WPLCR/PPLR when
compared to carriers of Met/Val genotypes. Better perfor-
mance in several neurocognitive tests in carriers of Met/
Val genotype in our patients with dementia is in agree-
ment with the findings that healthy older adults with
Val/Met genotype performed better on measures of ver-
bal declarative memory and delayed recall than both
homozygous groups20. The similar age range between
our and former20 study might suggest that younger sub-
jects who are Met/Met homozygotes have the optimal do-
pamine signaling in the prefrontal cortex, while in older
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TABLE 2
COMPARISONS OF THE DEMOGRAPHIC AND COGNITIVE PERFORMANCES AMONG THE COMT VAL/158MET GENOTYPIC GROUPS IN
PATIENTS WITH DEMENTIA
Dementia COMT
AA (Met/Met) N=11 AG (Met/Val) N=23 GG (Val/Val) N=12 ANOVA
Age 68.6±7.8 70.2±7.6 69.7±10.3 F=0.125; p=0.883; df=2,43
Duration of disease 2.4±1.3 2.0±1.8 3.3±2.2 F=1.869; p=0.167; df=2,43
Age at onset 66.2±7.7 68.2±7.7 66.4±10.3 F=0.258; p=0.754; df=2,43
Education 10.1±4.1 9.3±4.6 11.2±4.4 F=0.896; p=0.416; df=2,42
MMSE 12.3±5.7 17.8±7.1* 17.7±4.4** F=3.397; p=0.043; df=2,43
MMSE modified 42.4±23.5 56.6±22.2 60.4±17.7 F=2.165; p=0.127; df=2,42
CDT 4.2±2.8 5.0±2.4 5.9±1.8 F=1.552; p=0.224; df=2,43
ADAS 57±5.0 44.5±17.0 40.8±11.8 F=1.816; p=0.185; df=2,43
NPI 5.6±4.0 19.7±15.4 7.3±5.3 F=3.464; p=0.058; df=2,15
NPI depression 0.0±0.0 2.4±4.5 1.2±1.8 F=0.959; p=0.406; df=2,15
NPI anxiety 0.2±0.4 3.6±5.8 1.5±1.8 F=1.213; p=0.325; df=2,15
NPI euphoria 0.2±0.5 v1.3±2.4 0.0±0.0 F=1.362; p=0.286; df=2,15
NPI apathy 3.0±1.9 4.4±4.3 3.5±4.8 F=0.199; p=0.822; df=2,15
NPI desinhibition 0.2±0.5 0.9±1.6 0.7±1.6 F=0.333; p=0.722; df=2,15
NPI irritability 0.4±0.5 3.0±4.0 0.5±1.2 F=1.950; p=0.177; df=2,15
NPI aberrant behavior 1.6±3.6 4.1±5.6 0.0±0.0 F=1.807; p=0.198; df=2,15
(*p=0.031 vs. AA genotype; **p=0.015 vs. AA genotype; Tukey’s test)
TABLE 3
COMPARISONS OF THE COGNITIVE PERFORMANCES IN SUBJECTS DIVIDED INTO COMT VAL158/108MET GENOTYPES IN PATIENTS
WITH DEMENTIA. VAT, WPLCR/PPLR WORD PAIRS TIME OF CORRECT ANSWERS, WPLCR/PPLR WORD PAIRS TIME OF UNCORRECT
ANSWERS, REVERSE NAMING TIME CORRECT, REVERSE NAMING TIME UNCORRECT (SEC)
Dementia COMT
AA (Met/Met)
N=11
AG (Met/Val)
N=23
GG (Val/Val)
N=12
ANOVA
VAT duration/sec 1957±656 3738±5836 1828±245 F=0.785; p=0.465; df=2,30
VAT duration of letter test 936±584 869±84 955±155 F=0.388; p=0.682; df=2,30
VAT duration of numbers test 1020±257 840±96* 872±92 F=3.953; p=0.030; df=2,30
VAT time of response to letter test 412±414 239±84 325±155 F=1.815; p=0.180; df=2,30
VAT time of response to numbers test 390±257 210±96* 243±94 F=3.920; p=0.031; df=2,30
VAT average response of letter test 11.4±11.5 6.6±2.3 9.0±4.3 F=1.817; p=0.180; df=2,30
VAT average response of numbers test 10.8±7.1 5.8±2.6* 6.7±2.6 F=3.924; p=0.031; df=2,30
WPLCR/PPLR picture pairs – correct answers 6.3±5.4 10.0±5.6 9.6±6.1 F=0.976; p=0.388; df=2,31
WPLCR/PPLR picture pairs – uncorrect answers 17.0±9.1 19.8±5.4 20.0±6.2 F=0.502; p=0.610; df=2,31
WPLCR/PPLR unanswered 1.7±2.4 0.2±0.5** 0.4±0.7 F=4.103; p=0.026; df=2,31
WPLCR/PPLR time of correct answers 56.6±48.8 65.5±25.5 59.6±33.1 F=0.207; p=0.814; df=2,31
WPLCR/PPLR time of uncorrect answers 350.3±232.3 304.5±120.0 343.6±133.8 F=0.337; p=0.716; df=2,31
(* p=0.024 vs. AA genotype; **p=0.022 vs. AA genotype; Tukey’s test)
age, Met/Val heterozygotes have the optimal dopamine
signaling, since older age is related to reduced dopamine
signaling and prefrontal cortex function20. However, our
results are not in line with the previous data on the asso-
ciation of the COMT genotypes and various cognitive
functions in healthy subjects12,14,15,19,21,22, since carriers
of the Met/Met and Val/Met genotypes took less time to
perform the task on Trail Making test B19, showed better
performance on the Digit Span Forward (a measure of at-
tention and visuospatial working memory15), or on ma-
trix reasoning (a measure of nonverbal reasoning) and
block design (a measure of constructional ability), good
indicators of general reasoning ability and fluid intelli-
gence22, or on Letter number sequencing test12 (a test
that requires storage and manipulation of information)
and had decreased number of perseverantive errors in
Wisconsin Card Sorting Test and in Continuous Perfor-
mance Test14.
It has recently been reported that differences in the
effects of the COMT variants on the dopaminergic inputs
on cortical function, and therefore on cognitive func-
tions, might be induced by altered dopaminergic regula-
tion in health and disease23. Namely, schizophrenic pa-
tients who have impaired cortical dopaminergic tone,
with the Met/Met genotype (with lower dopamine degra-
dation) have more »normal« dopamine levels than pa-
tients with Val/Val genotype (which metabolize dopamine
more effectively). On the other hand, healthy subjects
with Val/Val genotype, i.e. those with increased dopamine
degradation, have optimal cortical dopaminergic activity
compared to control subjects with Met/Met genotype23.
In contrast, a recent review24 discussed the association
between indices of cognitive functions and COMT vari-
ants, and concluded that Met allele carriers perform
better than Val carriers in healthy subjects and in schizo-
phrenia patients, while carriers of Val allele show better
cognitive performances in ADHD and in Parkinson’s dis-
ease, suggesting a compley interplay between genetic, de-
velopmental and environmental backgrounds and patho-
physiological processes24. The opposing effects of Met/
Met, Met/Val or Val/Val genotypes on cognition might be
explained by the complexity of the cognitive functions as-
sessed by various cognitive tests22, by the significant ef-
fect of age, since COMT Val158/108Met polymorphism
modulates age-related changes in cortical physiology un-
derlying cognitive functions25, or by the significant gen-
der interaction with COMT genotypes to impact cogni-
tive function13. Since a myriad of genes is responsible for
memory and other cognitive functions, it has been pro-
posed that a constellation of genes, rather than a specific
gene per se, may be required to account for the majority
of variance in memory functioning21.
Some of the shortcommings of our study are the possi-
bilities of type 1 and type 2 errors due to the performance
of multiple cognitive tests and due to the modest size of
the groups, especially after subdivisions accordig to the
genotypes5. In order to avoid both types of errors, future
studies should include large samples.
Conclusion
Our preliminary data showed significantly impaired
performance in several neurocognitive tests in carriers of
Met/Met genotype in patients with dementia compared
to either Met/Val or Val/Val genotype carriers. Although
Met/Met genotype with more dopamine available in the
frontal cortex should be associated with better neurocog-
nitive test results than Met/Val or Val/Val genotype, our
data on demented patients did not confirm this hypothe-
sis. Further study on larger sample of patients with de-
mentia, that will have a large statistical power, is needed
to clarify the role of COMT polymorphism in cognitive
functions.
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ASOCIJACIJSKA STUDIJA FUNKCIONALNOG POLIMORFIZMA KATEHOL-O-METILTRANSFERAZE
I KOGNITIVNIH FUNKCIJA U BOLESNIKA S DEMENCIJOM
S A @ E T A K
Funkcionalni polimorfizam Val158/108Met katehol-o-metiltransferaze (COMT), koji se odlikuje zamjenom valina
(Val) i metionina (Met), povezan je s kognitivnim funkcijama u normalnommozgu, starijom dobi i raznim demencijama.
Katehol-o-metiltransferaza je odgovorna za razgradnju dopamina i drugih kateholamina, posebice u frontalnom kor-
teksu. Stoga je za o~ekivati da nosioci alela s ni`om aktivno{}u enzima (Met) imaju bolje rezultate odre|enih neuro-
kognitivnih testova. Studija je obuhvatila 46 bolesnika s demencijom i 46 zdravih starijih ispitanika. Bolesnicima je
utvr|eno neurolo{ko stanje koriste}i test MMSE (od eng. Mini Mental Status Examination) i niz razli~itih neurolo{kih
testova. Na uzorcima DNA provedena je genotipizacija. Bolesnici s demencijom su pokazali zna~ajne, o genotipu ovisne,
razlike u provedenim testovima. U odnosu na nosioce Val/Val genotipa, nosioci genotipa Met/Met su imali zna~ajno ni`e
rezultate na MMSE, zna~ajno du`e vrijeme trajanje, vrijeme odgovora i prosjek odgovora brojeva na testu vizualnog
povezivanja (eng. Visual Association Test; VAT) te znatno ve}i ve}i broj neodgovorenih pitanja na testu WPLCR/PPLR
(od eng. Word Pairs Learning and Recall/Picture Pairs Learning and Recall). Preliminarni rezultati su pokazali da
bolesnici s demencijom, koji su nosioci genotipa Met/Met, ostvaruju zna~ajno lo{ije rezultate na razli~itim neurokogni-
tivnim testovima u odnosu na bolesnike nosioce genotipova Val/Val ili Val/Met. Iako bi genotip Met/Met trebao biti
povezan s vi{e raspolo`ivog dopamina u frontalnom korteksu, {to se povezuje s boljim rezultatima neurokognitivnih
testova u tih bolesnika, na{i podaci nisu potvrdili tu hipotezu. Kako bi se razjasnila uloga polimorfizma COMT u kogni-
tivnim funkcijama, potrebne su daljnje studije s ve}im brojem ispitanika.
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